Bezard E

Spatial lipidomics reveals brain region-specific changes of sulfatides in an experimental MPTP Parkinson's disease primate model.

Kaya I, Nilsson A, Luptáková D, ..., Bezard E, Andrén PE

NPJ Parkinsons Dis 9 (1) 118 [2023-07-26; online 2023-07-26]

Spatial Mass Spectrometry [Technology development]

Basal ganglia neuropeptides show abnormal processing associated with L-DOPA-induced dyskinesia.

Hulme H, Fridjonsdottir E, Vallianatou T, ..., Bezard E, Andrén PE

NPJ Parkinsons Dis 8 (1) 41 [2022-04-13; online 2022-04-13]

Spatial Mass Spectrometry [Technology development]

Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA-induced dyskinesia.

Fridjonsdottir E, Shariatgorji R, Nilsson A, ..., Bezard E, Andrén PE

Sci Adv 7 (2) - [2021-01-00; online 2021-01-06]

Spatial Mass Spectrometry [Technology development]

µ Opioid Receptor Agonism for L-DOPA-Induced Dyskinesia in Parkinson's Disease.

Bezard E, Li Q, Hulme H, ..., Andren PE, Crossman AR

J. Neurosci. 40 (35) 6812-6819 [2020-08-26; online 2020-07-20]

Spatial Mass Spectrometry [Collaborative]

Comprehensive mapping of neurotransmitter networks by MALDI-MS imaging.

Shariatgorji M, Nilsson A, Fridjonsdottir E, ..., Odell LR, Andrén PE

Nat. Methods 16 (10) 1021-1028 [2019-10-00; online 2019-09-23]

Spatial Mass Spectrometry [Technology development]